


# Adtec SteriPlas cold plasma efficacy for the treatment of Acne Vulgaris

LONDON, UNITED KINGDOM, November 4, 2020 /EINPresswire.com/ -- We are excited to announce the recent publication, "Cold atmospheric plasma (CAP) as a promising therapeutic option for mild to moderate acne vulgaris" which features our Adtec SteriPlas cold plasma medical device for the treatment of acne

The paper created by Dr Arisi from the Department of [Dermatology](#) at the University of Brescia, Italy demonstrates the antibacterial efficacy of our patented cold plasma for the treatment of acne vulgaris patients. It indicates the significant reduction of acne skin lesions in treated patients who were previously unsuccessfully treated with topical drugs. Unlike topical drugs, the Adtec SteriPlas demonstrated a safe, effective, and well-tolerated treatment option with no side effects for the treatment of acne patients.

No adverse effects or skin reactions were reported either during the treatment nor at 3-months follow-up. Treatment was completely painless and well tolerated. Patients did not report itching or burning sensation during plasma application and in the following days.



The full paper can be found here:

<https://www.sciencedirect.com/science/article/pii/S2212816620300172>

Adtec Healthcare

Adtec Healthcare

+44 20 8737 5500

[info@adtecplasma.com](mailto:info@adtecplasma.com)

Visit us on social media:

[Facebook](#)

[Twitter](#)

[LinkedIn](#)



---

This press release can be viewed online at: <https://www.einpresswire.com/article/529958598>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2020 IPD Group, Inc. All Right Reserved.